Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 4

1(20.0%)

N/A

1(20.0%)

5Total

Phase 3(3)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02065882Phase 3Completed

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Role: collaborator

NCT02144077Phase 3Completed

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Role: collaborator

NCT01453179Phase 4Completed

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)

Role: collaborator

NCT02553239Not ApplicableTerminated

CoolLoop Paroxysmal Atrial Fibrillation

Role: collaborator

NCT02799069Phase 3Completed

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Role: collaborator

All 5 trials loaded